請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47536
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.author | Yu-Chin Chiu | en |
dc.contributor.author | 邱予芹 | zh_TW |
dc.date.accessioned | 2021-06-15T06:04:47Z | - |
dc.date.available | 2020-12-31 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-16 | |
dc.identifier.citation | 1. Stolnik, S.; Shakesheff, K., Formulations for delivery of therapeutic proteins.
Biotechnol Lett 2009, 31 (1), 1-11. 2. Weisbart, R. H.; Miller, C. W.; Chan, G.; Wakelin, R.; Ferreri, K.; Koeffler, H. P., Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. Cancer Lett 2003, 195 (2), 211-9. 3. Torchilin, V. P., Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006, 8, 343-75. 4. Kueltzo, L. A.; Middaugh, C. R., Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems. J Pharm Sci 2003, 92 (9), 1754-72. 5. Chakrabarti, R.; Wylie, D. E.; Schuster, S. M., Transfer of monoclonal antibodies into mammalian cells by electroporation. J Biol Chem 1989, 264 (26), 15494-500. 6. Torchilin, V. P., Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4 (2), 145-60. 7. Udhrain, A.; Skubitz, K. M.; Northfelt, D. W., Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomedicine 2007, 2 (3), 345-52. 8. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65 (1-2), 271-84. 9. Kataoka, G. S. K. a. K., Block copolymer micelles as long-circulating drug vehicles Block copolymer micelles as long-circulating drug vehicles 1995, 16, 295-309. 10. Pooga, M.; Hallbrink, M.; Zorko, M.; Langel, U., Cell penetration by transportan. FASEB J 1998, 12 (1), 67-77. 11. Hallbrink, M.; Floren, A.; Elmquist, A.; Pooga, M.; Bartfai, T.; Langel, U., Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 2001, 1515 (2), 101-9. 12. Frankel, A. D.; Pabo, C. O., Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55 (6), 1189-93. 13. Green, M.; Loewenstein, P. M., Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988, 55 (6), 1179-88. 14. Joliot, A.; Pernelle, C.; Deagostini-Bazin, H.; Prochiantz, A., Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 1991, 88 (5), 1864-8. 15. Elliott, G.; O'Hare, P., Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997, 88 (2), 223-33. 16. Schwarze, S. R.; Dowdy, S. F., In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000, 21 (2), 45-8. 17. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L. L.; Pepinsky, B.; Barsoum, J., Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994, 91 (2), 664-8. 18. Yoon, H. Y.; Lee, S. H.; Cho, S. W.; Lee, J. E.; Yoon, C. S.; Park, J.; Kim, T. U.; Choi, S. Y., TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells. Neurochem Int 2002, 41 (1), 37-42. 19. Cao, G.; Pei, W.; Ge, H.; Liang, Q.; Luo, Y.; Sharp, F. R.; Lu, A.; Ran, R.; Graham, S. H.; Chen, J., In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci 2002, 22 (13), 5423-31. 20. Snyder, E. L.; Dowdy, S. F., Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 2001, 3 (2), 147-52. 21. Kwon, H. Y.; Eum, W. S.; Jang, H. W.; Kang, J. H.; Ryu, J.; Ryong Lee, B.; Jin, L. H.; Park, J.; Choi, S. Y., Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett 2000, 485 (2-3), 163-7. 22. (a) de Lima, C. S.; Marques, M. A.; Debrie, A. S.; Almeida, E. C.; Silva, C. A.; Brennan, P. J.; Sarno, E. N.; Menozzi, F. D.; Pessolani, M. C., Heparin-binding hemagglutinin (HBHA) of Mycobacterium leprae is expressed during infection and enhances bacterial adherence to epithelial cells. FEMS Microbiol Lett 2009, 292 (2), 162-9; (b) Locht, C.; Hougardy, J. M.; Rouanet, C.; Place, S.; Mascart, F., Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 2006, 86 (3-4), 303-9; (c) Pethe, K.; Alonso, S.; Biet, F.; Delogu, G.; Brennan, M. J.; Locht, C.; Menozzi, F. D., The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001, 412 (6843), 190-4. 23. Ratcliffe, H. L., Tuberculosis induced by droplet nuclei infection; pulmonary tuberculosis of predetermined initial intensity in mammals. Am J Hyg 1952, 55 (1), 36-47. 24. Vidal Pessolani, M. C.; Marques, M. A.; Reddy, V. M.; Locht, C.; Menozzi, F. D., Systemic dissemination in tuberculosis and leprosy: do mycobacterial adhesins play a role? Microbes Infect 2003, 5 (7), 677-84. 25. Shepard, C. C., Growth characteristics of tubercle bacilli and certain other mycobacteria in HeLa cells. J Exp Med 1957, 105 (1), 39-48. 26. Menozzi, F. D.; Rouse, J. H.; Alavi, M.; Laude-Sharp, M.; Muller, J.; Bischoff, R.; Brennan, M. J.; Locht, C., Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 1996, 184 (3), 993-1001. 27. Menozzi, F. D.; Bischoff, R.; Fort, E.; Brennan, M. J.; Locht, C., Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci U S A 1998, 95 (21), 12625-30. 28. Delogu, G.; Brennan, M. J., Functional domains present in the mycobacterial hemagglutinin, HBHA. J Bacteriol 1999, 181 (24), 7464-9. 29. Menozzi, F. D.; Reddy, V. M.; Cayet, D.; Raze, D.; Debrie, A. S.; Dehouck, M. P.; Cecchelli, R.; Locht, C., Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect 2006, 8 (1), 1-9. 30. Verbelen, C.; Dupres, V.; Raze, D.; Bompard, C.; Locht, C.; Dufrene, Y. F., Interaction of the mycobacterial heparin-binding hemagglutinin with actin, as evidenced by single-molecule force spectroscopy. J Bacteriol 2008, 190 (23), 7614-20. 31. Pethe, K.; Aumercier, M.; Fort, E.; Gatot, C.; Locht, C.; Menozzi, F. D., Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin. J Biol Chem 2000, 275 (19), 14273-80. 32. 鄭如辰. 研究肝素結合凝血附著素相關胜肽之穿胞運輸性質. National Taiwan University, 2009. 33. Strahler, A. N., Science and Earth History. 1997; p 348. 34. Salemme, F. R., Structure and function of cytochromes c. Annu Rev Biochem 1977, 46, 299-329. 35. Giege, P.; Grienenberger, J. M.; Bonnard, G., Cytochrome c biogenesis in mitochondria. Mitochondrion 2008, 8 (1), 61-73. 36. Liu, X.; Kim, C. N.; Yang, J.; Jemmerson, R.; Wang, X., Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86 (1), 147-57. 37. Hague, A.; Paraskeva, C., Apoptosis and disease: a matter of cell fate. Cell Death Differ 2004, 11 (12), 1366-72. 38. Kimball, J. W., Kimball's Biology 39. Ferraro, E.; Pulicati, A.; Cencioni, M. T.; Cozzolino, M.; Navoni, F.; di Martino, S.; Nardacci, R.; Carri, M. T.; Cecconi, F., Apoptosome-deficient cells lose cytochrome c through proteasomal degradation but survive by autophagy-dependent glycolysis. Mol Biol Cell 2008, 19 (8), 3576-88. 40. Barnes, M. P.; Shen, W. C., Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells. Int J Pharm 2009, 369 (1-2), 79-84. 41. Ormerod, M. G.; Orr, R. M.; Peacock, J. H., The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 1994, 69 (1), 93-100. 42. Yeatman, T. J.; Risley, G. L.; Brunson, M. E., Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg 1991, 126 (11), 1376-81; discussion 1381-2. 43. Lamb, J.; Wheatley, D. N., Single amino acid (arginine) deprivation induces G1 arrest associated with inhibition of cdk4 expression in cultured human diploid fibroblasts. Exp Cell Res 2000, 255 (2), 238-49. 44. (a) Gong, H.; Zolzer, F.; von Recklinghausen, G.; Havers, W.; Schweigerer, L., Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 2000, 14 (5), 826-9; (b) Shen, L. J.; Beloussow, K.; Shen, W. C., Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 2006, 231 (1), 30-5. 45. (a) Ni, Y.; Schwaneberg, U.; Sun, Z. H., Arginine deiminase, a potential anti-tumor drug. Cancer Lett 2008, 261 (1), 1-11; (b) Curley, S. A.; Bomalaski, J. S.; Ensor, C. M.; Holtsberg, F. W.; Clark, M. A., Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology 2003, 50 (53), 1214-6. 46. Carlsson, J.; Drevin, H.; Axen, R., Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J 1978, 173 (3), 723-37. 47. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65 (1-2), 55-63. 48. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82 (13), 1107-12. 49. Conn's biological stains : a handbook of dyes, stains and fluorochromes for use in biology and medicine. 10th ed.; BIOS Scientific Publishers, Oxford, UK: 2002. 50. Vichai, V.; Kirtikara, K., Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1 (3), 1112-6. 51. Misawa, S.; Aoshima, M.; Takaku, H.; Matsumoto, M.; Hayashi, H., High-level expression of Mycoplasma arginine deiminase in Escherichia coli and its efficient renaturation as an anti-tumor enzyme. J Biotechnol 1994, 36 (2), 145-55. 52. Potocky, T. B.; Menon, A. K.; Gellman, S. H., Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J Biol Chem 2003, 278 (50), 50188-94. 53. Sheng, J.; Oyler, G.; Zhou, B.; Janda, K.; Shoemaker, C. B., Identification and characterization of a novel cell-penetrating peptide. Biochem Biophys Res Commun 2009, 382 (2), 236-40. 54. Pooga, M.; Kut, C.; Kihlmark, M.; Hallbrink, M.; Fernaeus, S.; Raid, R.; Land, T.; Hallberg, E.; Bartfai, T.; Langel, U., Cellular translocation of proteins by transportan. FASEB J 2001, 15 (8), 1451-3. 55. Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285 (5433), 1569-72. 56. Li, F.; Srinivasan, A.; Wang, Y.; Armstrong, R. C.; Tomaselli, K. J.; Fritz, L. C., Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 1997, 272 (48), 30299-305. 57. Zhivotovsky, B.; Orrenius, S.; Brustugun, O. T.; Doskeland, S. O., Injected cytochrome c induces apoptosis. Nature 1998, 391 (6666), 449-50. 58. Chang, S. H.; Phelps, P. C.; Berezesky, I. K.; Ebersberger, M. L., Jr.; Trump, B. F., Studies on the mechanisms and kinetics of apoptosis induced by microinjection of cytochrome c in rat kidney tubule epithelial cells (NRK-52E). Am J Pathol 2000, 156 (2), 637-49. 59. Okada, C. Y.; Rechsteiner, M., Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 1982, 29 (1), 33-41. 60. Gilmore, K. J.; Quinn, H. E.; Wilson, M. R., Pinocytic loading of cytochrome c into intact cells specifically induces caspase-dependent permeabilization of mitochondria: evidence for a cytochrome c feedback loop. Cell Death Differ 2001, 8 (6), 631-9. 61. Santra, S.; Kaittanis, C.; Perez, J. M., Cytochrome c Encapsulating Theranostic Nanoparticles: A Novel Bifunctional System for Targeted Delivery of Therapeutic Membrane-Impermeable Proteins to Tumors and Imaging of Cancer Therapy. Mol Pharm 2010. 62. Park, H. S.; Kim, C. W.; Lee, H. J.; Choi, J. H.; Lee, S. G.; Yun, Y. P.; Kwon, I. C.; Lee, S. J.; Jeong, S. Y.; Lee, S. C., A mesoporous silica nanoparticle with charge-convertible pore walls for efficient intracellular protein delivery. Nanotechnology 2010, 21 (22), 225101. 63. (a) Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R., Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990, 82 (13), 1113-8; (b) Perez, R. P.; Godwin, A. K.; Handel, L. M.; Hamilton, T. C., A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 1993, 29A (3), 395-9; (c) Wu, F. Y.; Liao, W. C.; Chang, H. M., Comparison of antitumor activity of vitamins K1, K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci 1993, 52 (22), 1797-804. 64. Fricker, S. P.; Buckley, R. G., Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. Anticancer Res 1996, 16 (6B), 3755-60. 65. Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Pinedo, H. M., Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991, 27 (7), 897-900. 66. (a) Henriksson, E.; Kjellen, E.; Wahlberg, P.; Wennerberg, J.; Kjellstrom, J. H., Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays. In Vitro Cell Dev Biol Anim 2006, 42 (10), 320-3; (b) Vistica, D. T.; Skehan, P.; Scudiero, D.; Monks, A.; Pittman, A.; Boyd, M. R., Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 1991, 51 (10), 2515-20. 67. Lee, M. J.; Kim, D. W.; Lee, Y. P.; Jeong, H. J.; Kang, H. W.; Shin, M. J.; Sohn, E. J.; Kim, M. J.; Jang, S. H.; Kang, T. C.; Won, M. H.; Min, B. H.; Cho, S. W.; Lee, K. S.; Park, J.; Eum, W. S.; Choi, S. Y., Inhibition of LPS-induced nitric oxide production by transduced Tat-arginine deiminase fusion protein in Raw 264.7 cells. BMB Rep 2009, 42 (5), 286-92. 68. Holtsberg, F. W.; Ensor, C. M.; Steiner, M. R.; Bomalaski, J. S.; Clark, M. A., Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002, 80 (1-3), 259-71. 69. Shen, L. J.; Lin, W. C.; Beloussow, K.; Shen, W. C., Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 2003, 191 (2), 165-70. 70. Saito, G.; Swanson, J. A.; Lee, K. D., Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55 (2), 199-215. 71. Garnett, M. C., Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 2001, 53 (2), 171-216. 72. (a) Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E., Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261 (5118), 212-5; (b) Hamann, P. R.; Hinman, L. M.; Hollander, I.; Beyer, C. F.; Lindh, D.; Holcomb, R.; Hallett, W.; Tsou, H. R.; Upeslacis, J.; Shochat, D.; Mountain, A.; Flowers, D. A.; Bernstein, I., Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002, 13 (1), 47-58. 73. Choi, S.; Lee, K. D., Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate. J Control Release 2008, 131 (1), 70-6. 74. Stein, S.; Weiss, A.; Adermann, K.; Lazarovici, P.; Hochman, J.; Wellhoner, H., A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)Tat neutralizes tetanus toxin inside chromaffin cells. FEBS Lett 1999, 458 (3), 383-6. 75. Kam, N. W.; Liu, Z.; Dai, H., Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005, 127 (36), 12492-3. 76. Duvall, C. L.; Convertine, A. J.; Benoit, D. S.; Hoffman, A. S.; Stayton, P. S., Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol Pharm 2010, 7 (2), 468-76. 77. (a) Wright, J. E.; Gittens, S. A.; Bansal, G.; Kitov, P. I.; Sindrey, D.; Kucharski, C.; Uludag, H., A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages. Biomaterials 2006, 27 (5), 769-84; (b) Youngblood, D. S.; Hatlevig, S. A.; Hassinger, J. N.; Iversen, P. L.; Moulton, H. M., Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 2007, 18 (1), 50-60. 78. (a) Wittrock, S.; Becker, T.; Kunz, H., Synthetic vaccines of tumor-associated glycopeptide antigens by immune-compatible thioether linkage to bovine serum albumin. Angew Chem Int Ed Engl 2007, 46 (27), 5226-30; (b) Jung, J. E.; Wollscheid, H. P.; Marquardt, A.; Manea, M.; Scheffner, M.; Przybylski, M., Functional ubiquitin conjugates with lysine-epsilon-amino-specific linkage by thioether ligation of cysteinyl-ubiquitin peptide building blocks. Bioconjug Chem 2009, 20 (6), 1152-62. 79. (a) Fahraeus, R.; Paramio, J. M.; Ball, K. L.; Lain, S.; Lane, D. P., Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 1996, 6 (1), 84-91; (b) Zaro, J. L.; Shen, W. C., Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells. J Control Release 2005, 108 (2-3), 409-17. 80. (a) Troy, C. M.; Derossi, D.; Prochiantz, A.; Greene, L. A.; Shelanski, M. L., Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J Neurosci 1996, 16 (1), 253-61; (b) Allinquant, B.; Hantraye, P.; Mailleux, P.; Moya, K.; Bouillot, C.; Prochiantz, A., Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol 1995, 128 (5), 919-27. 81. (a) Wan, J. S.; Persiani, S.; Shen, W. C., Transcellular processing of disulfide- and thioether-linked peroxidase--polylysine conjugates in cultured MDCK epithelial cells. J Cell Physiol 1990, 145 (1), 9-15; (b) Morgan, A. C., Jr.; Sivam, G.; Beaumier, P.; McIntyre, R.; Bjorn, M.; Abrams, P. G., Immunotoxins of Pseudomonas exotoxin A (PE): effect of linkage on conjugate yield, potency, selectivity and toxicity. Mol Immunol 1990, 27 (3), 273-82; (c) Trail, P. A.; Willner, D.; Knipe, J.; Henderson, A. J.; Lasch, S. J.; Zoeckler, M. E.; TrailSmith, M. D.; Doyle, T. W.; King, H. D.; Casazza, A. M.; Braslawsky, G. R.; Brown, J.; Hofstead, S. J.; Greenfield, R. S.; Firestone, R. A.; Mosure, K.; Kadow, K. F.; Yang, M. B.; Hellstrom, K. E.; Hellstrom, I., Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res 1997, 57 (1), 100-5; (d) Erickson, H. K.; Widdison, W. C.; Mayo, M. F.; Whiteman, K.; Audette, C.; Wilhelm, S. D.; Singh, R., Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010, 21 (1), 84-92. 82. Zhao, M.; Kircher, M. F.; Josephson, L.; Weissleder, R., Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002, 13 (4), 840-4. 83. Fonseca, S. B.; Pereira, M. P.; Kelley, S. O., Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009, 61 (11), 953-64. 84. Morris, M. C.; Depollier, J.; Mery, J.; Heitz, F.; Divita, G., A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001, 19 (12), 1173-6. 85. Gorinsky, B. Protein Degradation. http://www.biochem.emory.edu/labs/genekdw/protdeg2000/home.html. 86. Takaku, H.; Takase, M.; Abe, S.; Hayashi, H.; Miyazaki, K., In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer 1992, 51 (2), 244-9. 87. Qi, L.; Nett, T. M.; Allen, M. C.; Sha, X.; Harrison, G. S.; Frederick, B. A.; Crawford, E. D.; Glode, L. M., Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Res 2004, 64 (6), 2090-5. 88. Kerr, D. E.; Vrudhula, V. M.; Svensson, H. P.; Siemers, N. O.; Senter, P. D., Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation. Bioconjug Chem 1999, 10 (6), 1084-9. 89. Pagel, J. M.; Lin, Y.; Hedin, N.; Pantelias, A.; Axworthy, D.; Stone, D.; Hamlin, D. K.; Wilbur, D. S.; Press, O. W., Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 2006, 108 (1), 328-36. 90. Jiang, X.; Wang, X., Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004, 73, 87-106. 91. Chen, X.; Plasencia, C.; Hou, Y.; Neamati, N., Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48 (4), 1098-106. 92. Lee, T. Y.; Wu, H. C.; Tseng, Y. L.; Lin, C. T., A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 2004, 64 (21), 8002-8. 93. Arnold, J. J.; Ahsan, F.; Meezan, E.; Pillion, D. J., Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci 2004, 93 (9), 2205-13. 94. Fuchs, S.; Otto, H.; Jehle, S.; Henklein, P.; Schluter, A. D., Fluorescent dendrimers with a peptide cathepsin B cleavage site for drug delivery applications. Chem Commun (Camb) 2005, (14), 1830-2. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47536 | - |
dc.description.abstract | 肝素結合凝血附著素(heparin-binding haemagglutinin adhesin,HBHA)的c-terminal區域已被認為是主掌HBHA蛋白與宿主肺部細胞附著作用的主要區段,此c-terminal區域主要含lysine(K)、alanine(A)、proline(P)三種胺基酸,且由KKAAPA(R1)和KKAAAKK(R2)這兩段片段重複排列而成。過去本實驗室將R1、R2這兩種片段依不同組合合成出六段胜肽:HBHAa (3R1)、HBHAb(3R1+1R2)、HBHAc(1R1+2R2)、HBHAd(2R1+2R2)、HBHAe(2R2)和全長HBHA的c-terminal區域(3R1+2R2),以人類肺部上皮癌細胞(A549)與人類結腸腺癌細胞(Caco-2)作為研究穿胞運送的模式細胞。結果顯示HBHAc 為具有結合、攝取及穿胞能力之最短HBHA相關胜肽序列。在本研究中,使用cytochrome c(Cyt c)及基因重組精胺酸去亞胺酶(recombinant arginine deiminase,rADI)其分子量分別是12 kDa及92 kDa當作模式蛋白質,以化學鍵結的方式或是分生技術,研究HBHAc運送不同大小蛋白質的能力,進一步探究不同的鍵結方法對於運送的效果是否有不同的影響。
首先將HBHAc標記上FITC螢光分子,從共軛焦螢光影像發現,投予HBHAc一小時後,HBHAc進入細胞內且分布於細胞質及細胞核中。Cyt c為細胞凋亡中的一個重要中間者,從粒線體釋出至細胞質中的Cyt c 會誘發細胞的凋亡反應。我們利用SPDP及Sulfo-SMPB linker以化學鍵結的方式將Cyt c和HBHAc以可還原的雙硫鍵及不可還原的硫醚鍵連接在一起,並純化之。投予Cyt c-HBHAc conjugates一小時後,共軛焦螢光影像發現兩種Cyt c-HBHAc conjugates不僅分布於細胞質也在細胞核中;在生物活性方面,兩種Cyt c-HBHAc conjugates皆顯著地抑制A549、MCF-7、Caco-2的細胞存活率,且兩種Cyt c-HBHAc conjugates彼此間無顯著差異。然而, 使用流式細胞儀配合Propidium iodide 評估細胞凋亡現象, Cytc-SPDP-HBHAc conjugates對於細胞週期並無顯著的影響。 另一方面,使用分子量較大的rADI 當作模式蛋白,rADI 可將精胺酸(Arginine)反應成瓜胺酸(Citrulline)和胺(ammonia),被認為是有潛力的抗癌藥物。使用分生技術製備HBHAc-rADI 質體,並用管柱純化此融合蛋白,MTT 發現HBHAc-rADI 融合蛋白相較於rADI 單獨投予,顯著地抑制MCF-7 的細胞生長;在單劑量或多劑量模式的比較中,多劑量投予HBHAc-rADI 融合蛋白比單劑量投予更明顯地抑制細胞生長。使用Ultra Performance Liquid Chromatography(UPLC)評估HBHAc-rADI 融合蛋白對於精胺酸和瓜胺酸含量的影響。投予10 mU/mL rADI或HBHAc-rADI 融合蛋白四天後,rADI 與HBHAc-rADI 融合蛋白皆使得細胞外的精胺酸下降,瓜胺酸增加,兩者間無顯著差異;控制組、rADI、HBHAc-rADI 融合蛋白投予下的細胞內精胺酸含量彼此間皆無顯著差異;但細胞內的瓜胺酸在HBHAc-rADI 融合蛋白投予下顯著地高於rADI 單獨投予(p<0.05);以細胞內瓜胺酸與精胺酸的比值(citrulline/arginine)來看,HBHAc-rADI 融合蛋白投予下顯著地高於rADI(p<0.01)及控制組(p<0.01),但單獨投予rADI 與控制組間無顯著差異。由這樣的結果推論rADI 被HBHAc已融合蛋白的方式運送進入細胞後,將細胞內的精胺酸水解成瓜胺酸。 總結,我們發現HBHAc 可以運送大分子進入細胞質及細胞核;利用化學鍵結形成conjugates 或是分生技術製備融合蛋白,皆可以有效的連接HBHAc 和蛋白質並成功地應用在蛋白質遞輸上。 | zh_TW |
dc.description.abstract | The c-terminal domain of heparin-binding haemagglutinin adhesin(HBHA) hasbeen considered as the primary domain to adhere to hosts’ pulmonary cells. Thec-terminal domain contains lysine(K), alanine(A), and proline(P), and is identifiedwith two different repeats, KKAAPA motif (R1) and KKAAAKK motif (R2). In thepast, we evaluated the characteristics of binding, uptake, and transport in six modifiedsequences of HBHA-related peptides, including HBHAa (3R1), HBHAb (3R1+1R2),HBHAc(1R1+2R2), HBHAd(2R1+2R2), HBHAe(2R2) and HBHA(3R1+2R2).HBHAc is the shortest peptide of HBHA related peptides with ability of binding, uptake, and transport in A549 and Caco-2 cells. Therefore, in this study, we demonstrated that HBHAc could deliver model proteins, cytochrome c(Cyt c)and recombinant arginine deiminase(rADI), into cells by chemical linkages and molecular biological techniques. Firstly, HBHAc was labeled with fluorescein isothiocyanate (FITC) to investigate the intracellular distribution. After 1 h incubation of HBHAc in A549 cells, HBHAc was found within cytoplasm and nucleus by confocal image. The conjugations of HBHAc and a model protein Cyt c, Cyt c-SPDP-HBHAc and Cyt c-SMPB-HBHAc, were prepared by disulfide linkage and thioether linkage, respectively. Both of conjugates were not only detected within cytoplasm and nucleus after 1 h incubation, but also significantly inhibited cell proliferation in A549, MCF-7, and Caco-2 at 3.2 μM of Cyt c conjugates compared to Cyt c treatment alone by MTT assay. There was no significant difference in the effect of different conjugates on the inhibition of cell proliferation. We also used flow cytometry to evaluate the apoptotic effect of Cyt c-HBHAc conjugates. However, the Cyt c-SPDP-HBHAc conjugates had no significant effect on cell cycle. rADI is an enzyme which hydrolyze arginine to citrulline and ammonia, and has been studied as a potential anti-cancer drug for arginine-auxotrophic tumors. We constructed HBHAc-rADI plasmid and purified HBHAc-rADI fusion protein. HBHAc-rADI fusion protein significantly inhibited cell proliferation in rADI-resistant MCF-7 cells by MTT assay. Subsequently, the effect of intracellular delivery of HBHAc-rADI on the amount of arginine and citrulline in culture medium and intracellular fluid was investigated by Ultra Performance Liquid Chromatography (UPLC). After four-day treatment of rADI and HBHAc-rADI fusion protein at 10 mU/mL, respectively, the depletion of extracellular arginine and proportional increase of citruline were observed, and there was no significant difference between each treatment. The concentration of intracellular arginine was similar in the cells under the treatment of rADI and HBHAc-rADI fusion protein compared to the controls. However, the concentration of intracellular citrulline under the treatment of HBHAc-rADI fusion protein was significantly higher than the one under the treatment of rADI. The ratio of intracellular citrulline to intracellular arginine under the treatment of HBHAc-rADI fusion protein was significant higher than the one under the treatment of rADI. Therefore, the results indicate that rADI was successfully delivered into cells in the form fusing with HBHAc and reserved the biological activity in the hydrolysis of intracellular arginine to citrulline.
In summary, we demonstrated that HBHAc can be used as a carrier for macromolecular delivery into cytoplasma and nucleus. Using chemical linkages and molecular biotechnology to produce fusion proteins of biological active proteins and HBHAc are both successfully applied in the delivery of proteins. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T06:04:47Z (GMT). No. of bitstreams: 1 ntu-99-R97423007-1.pdf: 2088986 bytes, checksum: e223a293bad5eff7fea95fbb0d3c4458 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 中文摘要.................................................. i
Abstract ............................................... iii 目錄 .................................................... vi 表目錄 .................................................. xi 縮寫表 ................................................. xii 第一章 緒論 .............................................. 1 1. 1 大分子藥物的發展及遞輸 .............................. 1 1.1. 1 微脂體(liposomes)及微胞(micelles) ............. 2 1.1. 2 細胞穿透分子(cell-penetrating molecules) ........ 3 1. 2 Heparin-binding haemagglutinin adhesin(HBHA)........ 4 1.2. 1 HBHA 蛋白的功能及功能片段 ......................... 4 1.2. 2 HBHA 與非吞噬細胞的附著及內化機制 ................. 5 1.2. 3 HBHA 的肺外擴散特性 ............................... 6 1.2. 4 HBHA 蛋白c-terminal 片段的發現與辨識(identification)......................................... 7 1.2. 5 HBHA 胜肽的結合(binding)、攝取(uptake)及穿胞運輸(transport)特性 ........................................ 8 1.3 細胞色素c(cytochrome c,Cyt c) ......................8 1. 4 精胺酸與基因重組精胺酸去亞胺酶 ...................... 9 第二章 實驗目的 ......................................... 11 第三章 實驗材料與方法 ................................... 13 3. 1 實驗材料 ........................................... 13 3. 2 細胞培養 ........................................... 13 3. 3 cytochrome c(Cyt c)的運輸 .........................14 3.3.1 Cyt c 與HBHAc 鍵結 ................................ 14 3.3.2 細胞存活分析 ...................................... 15 3.3.2.1 MTT assay ....................................... 15 3.3.2.2 細胞存活分析-SRB assay .......................... 16 3.3.3 流式細胞儀分析 .................................... 17 3.3.4 Cyt c-HBHAc conjugates 的攝取(uptake)試驗 ....... 17 3.3.4. 1 螢光素標記法(fluorescein labeling method)..... 17 3.6. 1 共軛焦螢光影像分析法 ............................. 19 3.4 rADI 的運輸 ......................................... 19 3.4.1 建構pTTQ18-HBHAc-rADI 質體 ........................ 19 3.4.2 pTTQ18-HBHAc-rADI 質體確認 ........................ 20 3.4.3 HBHAc-rADI fusion protein 表現及純化 .............. 20 3.4 .4 使用西方墨點法確認純化後的HBHAc-rADI fusion protein ................................................. 22 3.4.4.1 硫酸十二酯聚丙烯胺凝膠電泳法 .................... 22 3.4.4.2 轉印法 .......................................... 22 3.4.4.3 免疫轉漬法分析 .................................. 23 3.4.5 HBHAc-rADI fusion protein 濃度檢測 ................ 23 3.4.6 HBHAc-rADI fusion protein 活性檢測 ................ 24 3.4.7 以MTT assay 評估HBHAc-rADI fusion protein 的生物活性 ...................................................... 24 3.4.8 以UPLC assay 評估HBHAc-rADI fusion protein 的生物活性 ...................................................... 25 3.4.8.1 HBHAc-rADI fusion protein 投予及UPLC 樣品收集及處理 ...................................................... 25 3.4.8.2 細胞內外液去蛋白及衍生化 ........................ 26 3.4.8.3 使用UPLC 分析胺基酸 ............................. 26 第四章 實驗結果 ......................................... 28 4. 1 HBHAc 的細胞攝取及分布 ............................. 28 4. 2 Cyt c-SPDP-HBHAc conjugates 及Cyt c-Sulfo-SMPB-HBHAc conjugates 的製備 ....................................... 28 4. 3 Cyt c 及其與Cyt c-HBHAc conjugates 的細胞攝取情形 ...................................................... 28 4. 4 評估比較Cyt c-SPDP-HBHAc conjugates 及Cyt c-SMPB-HBHAc conjugates 的生物活性 ................................... 29 4. 5 HBHAc-rADI 融合蛋白的製備及確認 .................... 30 4. 6 HBHAc-rADI 融合蛋白的生物活性 ...................... 30 4. 7 HBHAc-rADI 融合蛋白對於細胞內胺基酸的影響 .......... 31 第五章 實驗討論 ......................................... 33 5. 1 HBHAc 的細胞攝取及分布 ............................. 33 5.2. 1 Cyt c 的運送及生物活性 ........................... 33 5.2. 2 rADI 的運送及生物活性 ............................ 35 5. 3 化學鍵結的特性對於Cyt c-HBHAc conjugates 在生物活性上的影響 .................................................... 36 5.3. 1 化學鍵結的種類 ................................... 37 5.3. 2 化學鍵結的比例 ................................... 38 5. 4 single dose 與multiple dose 投予HBHAc-rADI 融合蛋白的差異 ...................................................... 39 5. 5 化學鍵結(conjugation)與融合蛋白(fusion protein)的比較 ...................................................... 39 5. 6 本研究之實驗限制 ................................... 41 第六章 結論 ............................................. 42 第七章 參考文獻 ......................................... 80 | |
dc.language.iso | zh-TW | |
dc.title | 研究肝素結合凝血附著素c之蛋白質運送能力 | zh_TW |
dc.title | Investigation on the protein delivery of heparin-binding
haemagglutinin adhesin c(HBHAc) | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張富雄(Fu-Hsiung Chan),林文貞(Wen-Jen Lin),許麗卿(Lih-Ching Hsu) | |
dc.subject.keyword | 肝素結合凝血附著素,細胞色素c,基因重組精胺酸去亞胺酶,連接體,雙硫鍵,硫醚鍵,融合蛋白,蛋白質遞送, | zh_TW |
dc.subject.keyword | heparin-binding haemagglutinin adhesin,cytochrome c,recombinant arginine deiminase,conjugates,disulfide,thioether,fusion protein,protein delivery, | en |
dc.relation.page | 91 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 2.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。